National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

HARDBACK
price:$52.95
add to cart

Rights & Permissions

topleft topright

Vaccines for the 21st Century: A Tool for Decisionmaking (2000)
Institute of Medicine (IOM)

Citation Manager

. "Appendix 13: Insulin-Dependent Diabetes Mellitus." Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press, 2000.

Please select a format:

BibTeX EndNote RefMan


Page
236
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Vaccines for the 21st Century: A Tool for Decisionmaking

Table A13–1 Health Care Costs Associated with IDDM

 

% of Cases

Duration (years)

% with Care

Cost per Unit

Units per Case

Form of Treatment

First 20 years

100%

 

CONVENTIONAL THERAPY—70%

Treatment phase

Yearly

Hypoglycemia

20.00

20%

$500

1.0

Treatment of severe hypoglycemia

 

20.00

35%

$100

1.0

Treatment modification

Physician visits and diagnostics

20.00

35%

$150

4.0

Quarterly visit plus diagnostic

 

 

20.00

35%

$150

2.0

Semiannual visit plus diagnostic

20.00

35%

$150

1.0

Specialist visit plus diagnostic

20.00

35%

$50

1.0

Case management, counseling

Self-management

20.00

70%

$15

18.0

Insulin

 

20.00

70%

$100

12.0

Other supplies

INTENSIVE THERAPY—30%

Treatment phase

Yearly

Hypoglycemia

20.00

15%

$500

1.0

Treatment of severe hypoglycemia

Physician visits and diagnostics

20.00

30%

$150

1.0

Quarterly visit (endocrinologist)

 

 

20.00

30%

$500

1.0

Annual visit (e.g., ophthalmologist)

20.00

30%

$50

2.0

Case management, counseling

Self-management

20.00

30%

$16

24.0

Insulin

 

20.00

30%

$200

12.0

Other supplies

Remainder of life

100%

 

Page
236
Front Matter (R1-R12)
Executive Summary (1-10)
Introduction (11-16)
Progress in Vaccine Development (17-38)
Considerations of Candidate Vaccines (39-52)
Overview of Analytic Approach and Results (53-92)
Review of the Analytical Model (93-108)
Ethical Considerations and Caveats (109-122)
Observations (123-132)
References (133-142)
Appendix 1: Borrelia burgdorferi (143-148)
Appendix 2: Chlamydia (149-158)
Appendix 3: Coccidioides Immitis (159-164)
Appendix 4: Cytomegalovirus (165-172)
Appendix 5: Enterotoxigenic E. coli (173-176)
Appendix 6: Epstein-Barr Virus (177-180)
Appendix 7: Helicobacter pylori (181-188)
Appendix 8: Hepatitis C (189-194)
Appendix 9: Herpes Simplex Virus (195-206)
Appendix 10: Histoplasma capsulatum (207-212)
Appendix 11: Human Paillomavirus (213-222)
Appendix 12: Influenza A and B (223-232)
Appendix 13: Insulin-Dependent Diabetes Mellitus (233-238)
Appendix 14: Melanoma (239-244)
Appendix 15: Multiple Sclerosis (245-250)
Appendix 16: Mycobacterium tuberculosis (251-256)
Appendix 17: Neisseria gonnorrhea (257-266)
Appendix 18: Neisseria meningitidis (267-272)
Appendix 19: Parainfluenza Virus (273-278)
Appendix 20: Respiratory Syncytial Virus (279-284)
Appendix 21: Rheumatoid Arthritis (285-290)
Appendix 22: Rotavirus (291-294)
Appendix 23: Shigella (295-298)
Appendix 24: Streptococcus, Group A (299-304)
Appendix 25: Streptococcus, Group B (305-312)
Appendix 26: Streptococcus pneumoniae (313-322)
Appendix 27: Information on accessing Electronic Spreadsheets (323-324)
Appendix 28: Summary of Workshops (325-434)
Appendix 29: Questions Posed to Outside Experts and List of Responders (435-442)
Index (443-460)